ClinicalTrials.gg
CompletedNCT01952080Updated Jun 9, 2021Results posted

A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

A Phase 3 interventional study of teduglutide in Short Bowel Syndrome, sponsored by Shire. Completed at 19 sites in 2 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
8th of 20
42 · median 20
Started
2013
the only one that year
Phase 3
16 of 20
none open now
Registered
7th of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 16 in phase 3, and was the 7th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

This will be an open label, 4-cohort study. Non-randomized subjects will receive teduglutide in each of the 3 active cohorts. An attempt will be made to enroll additional subjects into an observational cohort who will receive standard of care. Three doses of teduglutide are to be investigated for 12 weeks. All subjects will be screened prior to the start of treatment (SOT) to establish baseline characteristics including safety, eligibility and nutritional support parameters.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

Keywords

  • SBS
  • Pediatric SBS
  • Short Bowel Syndrome
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Current history of SBS as a result of major intestinal resection, (eg, due to necrotizing enterocolitis, midgut volvulus, intestinal atresia, or gastroschisis) for at least 12 months prior to screening
  • Short bowel syndrome that requires parenteral nutrition/intravenous (PN/IV) support
  • Stable PN/IV support for at least 3 months prior to enrollment based upon the opinion of the investigator

Key Exclusion Criteria:

  • Serial transverse enteroplasty or any other bowel lengthening procedure performed within the past 3 months
  • Unstable absorption due to cystic fibrosis, untreated Hirschsprung's disease or known DNA abnormalities (ie, Familial Adenomatous Polyposis, Fanconi syndrome)
  • Evidence of obstruction on upper gastrointestinal (GI) series done within 6 months prior to screening
  • Major gastrointestinal surgical intervention within 3 months prior to screening (insertion of feeding tube or endoscopic procedure is allowed)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    teduglutide

    Open label teduglutide, subcutaneously injected.

    Drug: teduglutide

  • No intervention
    Standard of Care

Interventions

  • Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study

06

What researchers measure

Primary outcomes

  1. Percent Change in Parenteral Support [Parenteral Nutrition (PN)/Intravenous (IV)] Volume at Week 12

    Percent change in PN/IV from the Baseline Visit to Week 12 Visit.

    Time frame: Baseline, Week 12

  2. Percent Change in Parenteral Support (PN/IV) Volume at End of Treatment

    Percent change in PN/IV from the Baseline Visit to End of Treatment Visit.

    Time frame: Baseline, End of Treatment

  3. Percent Change in Parenteral Support (PN/IV) Volume at Week 16

    Percent change in PN/IV from the Baseline Visit to Week 16 Visit.

    Time frame: Baseline, Week 16

  4. Absolute Change in Parenteral Support (PN/IV) Volume at Week 12

    Absolute change in PN/IV from the Baseline Visit to Week 12 Visit.

    Time frame: Baseline, Week 12

  5. Absolute Change in Parenteral Support (PN/IV) Volume at End of Treatment

    Absolute change in PN/IV from the Baseline Visit to End of Treatment Visit.

    Time frame: Baseline, End of Treatment

  6. Absolute Change in Parenteral Support (PN/IV) Volume at Week 16

    Absolute change in PN/IV from the Baseline Visit to Week 16 Visit.

    Time frame: Baseline, Week 16

Other outcomes

  1. Percent Change in Enteral Support (EN) Volume From Baseline at Week 12

    Percent change in enteral support requirements at Week 12 (liters/week)

    Time frame: Baseline, Week 12

  2. Percent Change in Enteral Support (EN) Volume From Baseline at Week 16

    Percent change in enteral support requirements at Week 16 (liters/week)

    Time frame: Baseline, Week 16

  3. Absolute Change in Enteral Support (EN) Volume From Baseline at Week 12

    Absolute change in enteral support requirements at Week 12 (liters/week)

    Time frame: Baseline, Week 12

  4. Absolute Change in Enteral Support (EN) Volume From Baseline at Week 16

    Absolute change in enteral support requirements at Week 16 (liters/week)

    Time frame: Baseline, Week 16

07

Results

Posted Sep 14, 2015

Participant flow

Participant flow — Overall Study
MilestoneStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Started581415
Treated581415
Completed571414
Not completed0101
Withdrew: Withdrawal by subject0001
Withdrew: Protocol non-compliance0100

Outcome measures

PrimaryPercent Change in Parenteral Support [Parenteral Nutrition (PN)/Intravenous (IV)] Volume at Week 12

Percent change in PN/IV from the Baseline Visit to Week 12 Visit.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change in Parenteral Support [Parenteral Nutrition (PN)/Intravenous (IV)] Volume at Week 12
percent changeStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Percent Change in Parenteral Support [Parenteral Nutrition (PN)/Intravenous (IV)] Volume at Week 127.38 ± 12.756-9.95 ± 21.625-37.34 ± 26.422-39.11 ± 40.792
PrimaryPercent Change in Parenteral Support (PN/IV) Volume at End of Treatment

Percent change in PN/IV from the Baseline Visit to End of Treatment Visit.

Time frame:
Baseline, End of Treatment
Reported as:
Mean · percent change
Percent Change in Parenteral Support (PN/IV) Volume at End of Treatment
percent changeStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Percent Change in Parenteral Support (PN/IV) Volume at End of Treatment7.38 ± 12.756-8.60 ± 20.380-35.61 ± 26.198-36.50 ± 40.585
PrimaryPercent Change in Parenteral Support (PN/IV) Volume at Week 16

Percent change in PN/IV from the Baseline Visit to Week 16 Visit.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change in Parenteral Support (PN/IV) Volume at Week 16
percent changeStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Percent Change in Parenteral Support (PN/IV) Volume at Week 163.92 ± 16.616-11.25 ± 21.196-33.85 ± 27.017-31.80 ± 39.264
PrimaryAbsolute Change in Parenteral Support (PN/IV) Volume at Week 12

Absolute change in PN/IV from the Baseline Visit to Week 12 Visit.

Time frame:
Baseline, Week 12
Reported as:
Mean · Liters/week
Absolute Change in Parenteral Support (PN/IV) Volume at Week 12
Liters/weekStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Absolute Change in Parenteral Support (PN/IV) Volume at Week 120.43 ± 0.746-0.50 ± 0.910-2.78 ± 1.985-2.57 ± 3.564
Other pre-specifiedPercent Change in Enteral Support (EN) Volume From Baseline at Week 12

Percent change in enteral support requirements at Week 12 (liters/week)

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change in Enteral Support (EN) Volume From Baseline at Week 12
percent changeStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Percent Change in Enteral Support (EN) Volume From Baseline at Week 1216.82 ± 14.92123.50 ± 22.06050.93 ± 61.41657.96 ± 44.953
Other pre-specifiedPercent Change in Enteral Support (EN) Volume From Baseline at Week 16

Percent change in enteral support requirements at Week 16 (liters/week)

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change in Enteral Support (EN) Volume From Baseline at Week 16
percent changeStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Percent Change in Enteral Support (EN) Volume From Baseline at Week 1652.06 ± 66.19460.3043.98 ± 78.59958.93 ± 63.927
Other pre-specifiedAbsolute Change in Enteral Support (EN) Volume From Baseline at Week 12

Absolute change in enteral support requirements at Week 12 (liters/week)

Time frame:
Baseline, Week 12
Reported as:
Mean · Liters/week
Absolute Change in Enteral Support (EN) Volume From Baseline at Week 12
Liters/weekStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Absolute Change in Enteral Support (EN) Volume From Baseline at Week 120.69 ± 0.7152.67 ± 4.4122.64 ± 3.2200.97 ± 1.127
Other pre-specifiedAbsolute Change in Enteral Support (EN) Volume From Baseline at Week 16

Absolute change in enteral support requirements at Week 16 (liters/week)

Time frame:
Baseline, Week 16
Reported as:
Mean · Liters/week
Absolute Change in Enteral Support (EN) Volume From Baseline at Week 16
Liters/weekStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Absolute Change in Enteral Support (EN) Volume From Baseline at Week 160.84 ± 0.6244.56 ± 5.3842.47 ± 3.4030.91 ± 0.968
PrimaryAbsolute Change in Parenteral Support (PN/IV) Volume at End of Treatment

Absolute change in PN/IV from the Baseline Visit to End of Treatment Visit.

Time frame:
Baseline, End of Treatment
Reported as:
Mean · Liters/week
Absolute Change in Parenteral Support (PN/IV) Volume at End of Treatment
Liters/weekStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Absolute Change in Parenteral Support (PN/IV) Volume at End of Treatment0.43 ± 0.746-0.43 ± 0.864-2.73 ± 1.916-2.4 ± 3.498
PrimaryAbsolute Change in Parenteral Support (PN/IV) Volume at Week 16

Absolute change in PN/IV from the Baseline Visit to Week 16 Visit.

Time frame:
Baseline, Week 16
Reported as:
Mean · Liters/week
Absolute Change in Parenteral Support (PN/IV) Volume at Week 16
Liters/weekStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Absolute Change in Parenteral Support (PN/IV) Volume at Week 160.17 ± 1.027-0.56 ± 0.885-2.56 ± 1.917-1.99 ± 3.092

Adverse events

Collected over Adverse event data were collected from the first patient consent signed through last subject last visit for a duration of 421 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care—3/5 (60%)5/5 (100%)
Teduglutide 0.0125 mg/kg/Day—3/8 (37.5%)8/8 (100%)
Teduglutide 0.025 mg/kg/Day—6/14 (42.9%)14/14 (100%)
Teduglutide 0.05 mg/kg/Day—8/15 (53.3%)15/15 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
PyrexiaGeneral disorders2/50/81/143/15
Central line infectionInfections and infestations0/50/83/141/15
Catheter related complicationGeneral disorders1/50/82/141/15
FungaemiaInfections and infestations1/50/80/140/15
Gastroenteritis viralInfections and infestations1/50/80/140/15
Viral infectionInfections and infestations1/50/80/140/15
Adenovirus infectionInfections and infestations0/51/80/140/15
Catheter related infectionInfections and infestations0/51/80/140/15
InfluenzaInfections and infestations0/51/80/140/15
Abdominal DistensionGastrointestinal disorders0/50/81/140/15
Most frequent other events
Showing 10 of 60
Most frequent other events
EventStandard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/Day
Gastrointestinal stoma complicationInjury, poisoning and procedural complications—0/10/11/1
VomitingGastrointestinal disorders0/50/85/147/15
PyrexiaGeneral disorders2/50/82/147/15
Upper respiratory tract infectionInfections and infestations2/52/84/144/15
Blood bicarbonate decreasedInvestigations2/51/81/143/15
Catheter related complicationGeneral disorders1/53/84/142/15
Abdominal painGastrointestinal disorders1/51/81/144/15
FatigueGeneral disorders0/50/81/144/15
CoughRespiratory, thoracic and mediastinal disorders1/51/82/144/15
FlatulenceGastrointestinal disorders0/52/81/140/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Standard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/DayTotal
Mean2.2 ± 0.455.1 ± 4.554.6 ± 3.434.5 ± 3.164.7 ± 3.5
Age, Customized
Age, Customized(Participants)Standard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/DayTotal
1 to 3 years546722
4 to 12 years037717
13 to 17 years01113
Sex: Female, Male
Sex: Female, Male(Participants)Standard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/DayTotal
Female223714
Male3611828
Region of Enrollment
Region of Enrollment(Participants)Standard of CareTeduglutide 0.0125 mg/kg/DayTeduglutide 0.025 mg/kg/DayTeduglutide 0.05 mg/kg/DayTotal
United States58141239
United Kingdom00033
08

Study locations

19 sites
  • Children´s Hospital of Alabama
    Birmingham, Alabama 35233, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90024, United States
  • Mattel Children's Hospital UCLA, Department of Pediatric Gastroenterology
    Los Angeles, California 90095, United States
  • Arnold Palmer Hospital for Children
    Orlando, Florida 32806, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children at IU Health
    Indianapolis, Indiana 46202, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Mott Children's Hospital, University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Childrens Mercy Hospitals & Clinics Pediatric Gastroenterology
    Kansas City, Missouri 64108, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • University of Tennessee Health Science Center Le Bonheur Pediatric Specialists
    Memphis, Tennessee 38103, United States
  • Monroe Carell, Jr. Children's Hospital at Vanderbilt
    Nashville, Tennessee 37232, United States
  • Texas Children's Hospital, Baylor College of Medicine
    Houston, Texas 77030, United States
  • Seattle Childrens Hospital Gastroenterology and Hepatology
    Seattle, Washington 98105, United States
  • University of Wisconsin School of Medicine and Public Health Surgery
    Madison, Wisconsin 53792, United States
  • Great Ormond Street Hospital for Children
    London, United Kingdom
09

References and documents

Publications

  • Carter BA, Cohran VC, Cole CR, Corkins MR, Dimmitt RA, Duggan C, Hill S, Horslen S, Lim JD, Mercer DF, Merritt RJ, Nichol PF, Sigurdsson L, Teitelbaum DH, Thompson J, Vanderpool C, Vaughan JF, Li B, Youssef NN, Venick RS, Kocoshis SA. Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome. J Pediatr. 2017 Feb;181:102-111.e5. doi: 10.1016/j.jpeds.2016.10.027. Epub 2016 Nov 15. PubMed 27855998 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Jan 2015, 13 months.

Results were first posted in Sep 2015, 8 months after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 13 months is below that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2013
First posted
Sep 27, 2013
StartActual
Nov 14, 2013
Primary completionActual
Jan 9, 2015
CompletionActual
Jan 9, 2015
Results first posted
Sep 14, 2015
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01952080
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Sep 27, 2013
Start date
Nov 14, 2013
Primary completion
Jan 9, 2015
Completion
Jan 9, 2015
Results posted
Sep 14, 2015
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion